STRUCTURAL STUDIES OF THE THYROTROPIN RECEPTOR AND G(S)ALPHA IN HUMANTHYROID CANCERS - LOW-PREVALENCE OF MUTATIONS PREDICTS INFREQUENT INVOLVEMENT IN MALIGNANT TRANSFORMATION
D. Spambalg et al., STRUCTURAL STUDIES OF THE THYROTROPIN RECEPTOR AND G(S)ALPHA IN HUMANTHYROID CANCERS - LOW-PREVALENCE OF MUTATIONS PREDICTS INFREQUENT INVOLVEMENT IN MALIGNANT TRANSFORMATION, The Journal of clinical endocrinology and metabolism, 81(11), 1996, pp. 3898-3901
The genes for either the TSH receptor (TSH-R) or the stimulatory guani
ne nucleotide-binding protein subunit (G(s) alpha) can undergo somatic
mutations in thyroid cells, leading to constitutive activation of ade
nylyl cyclase and the formation of clonal hyperfunctioning thyroid ade
nomas. Autonomously functioning thyroid adenomas are thought not to be
common precursors of thyroid cancer. If this is the case, mutations o
f the TSH-R or G(s) alpha would not be expected to be highly prevalent
in thyroid carcinomas. In this paper we report the results of a scree
n for structural defects in exon 10 of the TSH-R (which includes the w
hole serpentine structure, but not the extracellular domain) and of G(
s) alpha in 30 thyroid carcinomas. Five of these were from patients wi
th functioning metastasis, as we hypothesized that if mutations of the
se genes were to play a role in the progression to malignancy, they wo
uld be more likely to manifest in thyroid cancers that retain unusual
differentiated function (i.e. capable of synthesizing enough thyroid h
ormone to render patients euthyroid or hyperthyroid after total thyroi
dectomy). None of the 30 tumors had activating point mutations of G(s)
alpha. Only 2 of 30 had somatic mutations of the TSH-R (codon 632: AC
C to GCC, Thr to Ala; and ACC to ATC, Thr to Ile, respectively), the l
atter in a patient with a thyroid hormone-producing follicular carcino
ma. These results suggest that events leading to constitutive activati
on of the adenylate cyclase signal transduction cascade are not a freq
uent event in the progression toward differentiated thyroid carcinomas
.